In 2008, the National Toxicology Program (NTP) reported that very high levels of Cr(VI) in drinking water caused small intestine tumors in laboratory rodents at extremely high concentrations of Cr(VI) (equivalent to 60,000 and 180,000 ppb).
However, because of the study design, NTP could not examine the mode of action (MOA), meaning how the chemical can cause cancer at the cellular level of an organism. It could not predict how the tumors occurred, how to extrapolate these high dose observations to lower, naturally occurring levels in drinking water, or whether these high dose findings are of biological relevance to humans. To put the high NTP doses into perspective, the Agency for Toxic Substances and Disease Registry (ATSDR) notes that typical U.S. drinking water supplies contain total chromium levels within a range of 0.2 – 35 ug/L with most supplies in the United States containing less than 5 ug/L [5 ppb] of chromium. Most U.S. drinking water supplies contain total chromium levels far below the current EPA drinking water standard of 100 ppb for total chromium.
Because the NTP study did not examine mode of action, which is important for scientists and regulators to understand when evaluating risk, the Hexavalent Chromium Panel (the Panel) of the American Chemistry Council (ACC) agreed to sponsor extensive studies that investigated not only which levels of Cr(VI) in drinking water can result in adverse effects like cancer, but also how hexavalent chromium can cause cancer in rodents. The studies also developed data describing the differences between rodents and humans in their ability to process and detoxify hexavalent chromium.